http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-100396701-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c27f4a786895417d03d0b1045587100 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 |
| filingDate | 2005-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55e84319bc45501683d88419b9f6837e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b29cc52615b1faeed17adddb70d7dc82 |
| publicationDate | 2008-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-100396701-C |
| titleOfInvention | Fusion protein of extrasin alpha1 and interferon |
| abstract | The present invention relates to fusion protein of a thymic peptide and interferon, which comprises an amino acid sequence of a human thymic peptide alpha1 and an amino acid sequence of human interferon alpha2b, wherein the amino acid sequence of the human thymic peptide alpha1 is positioned at the amino terminal of the amino acid sequence of the human interferon alpha2b. The fusion protein has stronger antiviral activity than the standard reference material of the interferon alpha2b, and the fusion protein can strengthen the proliferation of T cells and inhibit the growth of tumor cells. Experiments indicate that the influence of the fusion protein on immune cell functions and antibody level is superior to that of single interferon alpha2b and single thymosin alpha1. |
| priorityDate | 2005-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 392.